Get the Stockscreener App
0.7674
4.41%
0.0324
After Hours:
.75
-0.0174
-2.27%
Seres Therapeutics Inc stock is traded at $0.7674, with a volume of 819.60K.
It is up +4.41% in the last 24 hours and down -12.83% over the past month.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
See More
Previous Close:
$0.735
Open:
$0.7389
24h Volume:
819.60K
Relative Volume:
0.32
Market Cap:
$131.02M
Revenue:
$126.33M
Net Income/Loss:
$-82.68M
P/E Ratio:
-1.279
EPS:
-0.6
Net Cash Flow:
$-79.98M
1W Performance:
-9.11%
1M Performance:
-12.83%
6M Performance:
-48.15%
1Y Performance:
-40.51%
1-Day Range:
$0.7389
$0.787
1-Week Range:
$0.711
$0.8379
52-Week Range:
$0.54
$1.53
Seres Therapeutics Inc Stock (MCRB) Company Profile
Name
Seres Therapeutics Inc
Sector
Industry
Phone
617 945 9626
Address
200 SIDNEY STREET, CAMBRIDGE, MA
Compare MCRB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
0.7674 | 131.02M | 126.33M | -82.68M | -79.98M | -0.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Apr-21-23 | Initiated | JP Morgan | Neutral |
| Jul-23-21 | Downgrade | Goldman | Neutral → Sell |
| May-18-21 | Resumed | Goldman | Neutral |
| Mar-05-21 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Sep-18-20 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-11-20 | Upgrade | Jefferies | Hold → Buy |
| Apr-30-19 | Initiated | Jefferies | Hold |
| Oct-22-18 | Initiated | Chardan Capital Markets | Buy |
| Oct-13-17 | Initiated | Oppenheimer | Outperform |
| Aug-04-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-01-17 | Reiterated | FBR & Co. | Outperform |
| Aug-12-16 | Reiterated | FBR Capital | Outperform |
| Aug-01-16 | Downgrade | BofA/Merrill | Buy → Neutral |
| Aug-01-16 | Reiterated | H.C. Wainwright | Buy |
| Jul-29-16 | Resumed | H.C. Wainwright | Buy |
| Mar-30-16 | Initiated | FBR Capital | Outperform |
| Mar-03-16 | Initiated | Guggenheim | Buy |
| Jan-25-16 | Initiated | H.C. Wainwright | Buy |
| Oct-22-15 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-22-15 | Initiated | Canaccord Genuity | Buy |
| Jul-21-15 | Initiated | Goldman | Neutral |
| Jul-21-15 | Initiated | Leerink Partners | Outperform |
View All
Seres Therapeutics Inc Stock (MCRB) Latest News
Seres Therapeutics receives $50 million from Nestlé Health Science - MSN
Microbiomes Market to Grow by USD 1.13 Billion (2024-2028), Driven by Rising Disease Prevalence; AI Impact on Market TrendsTechnavio - The Malaysian Reserve
Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale - The Manila Times
Seres Therapeutics Receives $50M Payment from Nestlé, Extends Cash Runway to 2026 - StockTitan
Seres Therapeutics Strengthens Future with VOWST Sale - TipRanks
Seres Therapeutics Provides Corporate Updates and Financial Results - Defense World
StockNews.com Downgrades Seres Therapeutics (NASDAQ:MCRB) to Sell - MarketBeat
Seres Therapeutics (NASDAQ:MCRB) Downgraded by StockNews.com to “Sell” - Defense World
Seres announces new translational biomarker results from SER-155 Phase 1b study - Yahoo Finance
Geode Capital Management LLC Acquires 255,014 Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) - Defense World
Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates - The Manila Times
Seres Therapeutics Announces New Translational Biomarker - GlobeNewswire
Seres' SER-155 Shows Breakthrough Results in Stem Cell Transplant Study, FDA Fast-Track Follows - StockTitan
State Street Corp Purchases 43,700 Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) - Defense World
Seres Therapeutics (NASDAQ:MCRB) Rating Increased to Hold at StockNews.com - Defense World
Seres Therapeutics (NASDAQ:MCRB) Raised to Hold at StockNews.com - MarketBeat
Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Above 50 Day Moving AverageTime to Sell? - MarketBeat
5 Best Microbiome Companies (January 2025) - Securities.io
The past three years for Seres Therapeutics (NASDAQ:MCRB) investors has not been profitable - Yahoo Finance
Charles Schwab Investment Management Inc. Has $708,000 Stake in Seres Therapeutics, Inc. (NASDAQ:MCRB) - Defense World
Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 200 Day Moving AverageHere's What Happened - MarketBeat
Seres Therapeutics to highlight plans for SER-155 at JPMorgan conference - Yahoo Finance
Biotech Biz Xilio Therapeutics Appoints Chief Legal Officer - Law360
Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer - citybiz
Xilio Therapeutics Strengthens Leadership Team, Appoints Seres Therapeutics Veteran as Chief Legal Officer - StockTitan
Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference - The Manila Times
Seres Therapeutics' Breakthrough Therapy Cuts Infection Risk by 77% in Stem Cell Transplants - StockTitan
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TTNP, MCRB, LLAP on Behalf of Shareholders - The Eastern Progress Online
Seres’ SER-155 gains breakthrough status for BSIs reduction - Yahoo Finance
MCRBSeres Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics' SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) - The Manila Times
FDA Grants Breakthrough Therapy Designation to Seres - GlobeNewswire
Seres' SER-155 Wins FDA Breakthrough Status After Stunning 77% Infection Reduction in Transplant Study - StockTitan
Seres Therapeutics (NASDAQ:MCRB) Downgraded to "Sell" Rating by StockNews.com - MarketBeat
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference - The Manila Times
Seres Therapeutics CEO to Present at Piper Sandler Healthcare Conference | MCRB Stock News - StockTitan
Seres Therapeutics CEO Eric Shaff sells shares worth $1,354 By Investing.com - Investing.com Nigeria
Seres Therapeutics Q3 2024 Earnings Preview - MSN
Seres Therapeutics CEO Eric Shaff sells shares worth $1,354 - Investing.com India
Microbiomes Market to Grow by USD 1.13 Billion (2024-2028), Rising Disease Prevalence Driving Revenue, with AI Powering Market EvolutionTechnavio - The Malaysian Reserve
Seres Therapeutics chief legal officer sells shares worth $474 - Investing.com
Seres Therapeutics chief legal officer sells shares worth $474 By Investing.com - Investing.com Australia
Seres Therapeutics executive sells shares worth $397 - Investing.com
Seres Therapeutics executive sells shares worth $397 By Investing.com - Investing.com Canada
Seres Therapeutics Receives Notification from Nasdaq Regarding Bid Price Requirement - Defense World
Seres Therapeutics Third Quarter 2024 Earnings: US$0.33 loss per share (vs US$0.37 loss in 3Q 2023) - Yahoo Finance
Canaccord Genuity Group Reiterates "Buy" Rating for Seres Therapeutics (NASDAQ:MCRB) - MarketBeat
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q3 2024 Earnings Call Transcript - Insider Monkey
Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: Strategic Moves and Clinical ... By GuruFocus - Investing.com Canada
Earnings call: Seres Therapeutics reports key Q3 2024 milestones - Investing.com
Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: - GuruFocus.com
Seres Therapeutics Inc Stock (MCRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
4.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):